UK court overturns
Genentech patent, cites Brexit in CJEU referral [Taltz (ixekizumab)]
The patents division of the English High Court has found
that a patent owned by Genentech is invalid and denied the biotechnology
company’s application for a supplementary protection certificate (SPC)…..
Last Remaining
Defendant Settles FTC Suit that Led to Landmark Supreme Court Ruling on Drug
Company “Reverse Payments” [AndroGel (Testosterone)]
The Federal Trade Commission has reached a settlement in FTC
v. Actavis, the 2009 FTC case alleging that the brand-name drug company Solvay
and three generic drug companies illegally agreed to restrict generic
competition to Solvay’s branded testosterone-replacement drug AndroGel for nine
years…..
Judge orders
Boehringer to disclose Humira biosimilar plans
A US judge has ordered Boehringer Ingelheim to release its
rollout plans for a biosimilar version of Humira (adalimumab), following a
request from AbbVie. On Friday, February 22, Judge Richard Lloret granted
AbbVie’s request to compel the release of more information about Boehringer’s
launch plans for the arthritis medication….
Hikma Case Set for
Supreme Court Consideration [Fanapt (iloperidone)]
Hikma Pharmaceuticals
USA Inc. v. Vanda Pharmaceuticals Inc. (Supreme Court 2019). Briefing is
now complete in this important eligibility case pending before the Supreme
Court. Hikma’s petition presents the following question.
Whether patents that claim a method of medically treating a
patient automatically satisfy Section 101 of the Patent Act, even if they apply
a natural law using only routine and conventional steps…..
No Sovereign Immunity for Patent-Asserting State
University
UF’s asserted patent is titled “Managing Critical Care
Physiologic Data Using Data Synthesis Technology.” U.S. Patent No.
7,062,251. From the patent title, keen
Patently-O readers will recognize a potential eligibility problem. N.D.Fla. District Court Judge Mark Walker
dismissed the case on a R.12(b)(6) motion without taking any evidence — finding
the asserted claims ineligible as a matter of law. On appeal, the Federal
Circuit has affirmed…..
Amgen prevails in
PCSK9 patent dispute with Regeneron and Sanofi
A Delaware jury has confirmed the validity of two Amgen patents covering high cholesterol med Repatha (evolocumab), specifically, the
antibodies that bind to a specific region on PCSK9 and reduce LDL-C
("bad" cholesterol) levels in the body. The verdict follows a March
2016 trial where competitors Regeneron Pharmaceuticals and Sanof admitted that their PCSK9 inhibitor Praluent (alirocumab) infringed on
Amgen's patents (unheld by a prior jury)……
Boehringer Must Show
How IP 'Thicket' Blocked Humira Rival
Law360 (February 25, 2019, 5:39 PM EST) -- Boehringer
Ingelheim must hand over its launch plans for a biosimilar version of AbbVie
Inc.’s hugely popular immunosuppressant Humira, a Delaware magistrate judge has
ruled in a patent infringement case, finding...
No comments:
Post a Comment